Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glimepiride + metformin + voglibose
- Development stage
- Unknown
- Lead developer
- Wings Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Glimixia is a Wings Biotech branded oral fixed-dose antidiabetic combination represented by the Glimixia VM products, containing **glimepiride + metformin + voglibose**. Glimepiride stimulates pancreatic insulin secretion by inhibiting beta-cell ATP-sensitive potassium channels through the sulfonylurea receptor; metformin lowers hepatic glucose production and improves insulin sensitivity through cellular energy-stress and AMP-activated protein kinase-related effects; and voglibose inhibits intestinal alpha-glucosidases, delaying carbohydrate digestion and postprandial glucose absorption. The Glimixia VM1 and VM2 extended-release tablet products are marketed for management of type 2 diabetes mellitus. ([wingsbiotech.in](https://www.wingsbiotech.in/html/diabetes-management.htm))
- Brand names
- Glimixia VM1Glimixia VM2Glimixia VM2 HD
- Other names
- glimepiride + metformin + voglibose
02
Targets
SUR1 (Sulfonylurea receptor 1)
Beyond the preview
Go deeper on glimepiride + metformin + voglibose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glimepiride + metformin + voglibose.